Article Text

other Versions

Download PDFPDF
Systematic review with meta-analysis
Most add-on therapies to metformin have similar effects on HbA1c
  1. Thomas Karagiannis1,
  2. Eleni Bekiari1,2
  1. 1Clinical Research and Evidence-Based Medicine Unit, Aristotle University Thessaloniki, Thessaloniki, Greece
  2. 2Second Medical Department, Diabetes Centre, Aristotle University Thessaloniki, Thessaloniki, Greece
  1. Correspondence to: Dr Thomas Karagiannis, Clinical Research and Evidence-Based Medicine Unit, Aristotle University Thessaloniki, 49 Konstantinoupoleos Street, Thessaloniki 54642, Greece; tkaragian{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlCrossRefPubMed


Current guidelines for type 2 diabetes recommend metformin as first-line therapy, but offer no conclusive guidance for choosing among at least six drug classes as add-on to metformin in patients in whom glycaemic targets are not met.1 In light of accumulating evidence for novel agents, it is imperative to update the comparative effectiveness and safety of available antidiabetic medications. Maruthur and colleagues have addressed this question through a recently published systematic review and meta-analysis, which assesses the effect of all commonly used glucose-lowering drug classes on long-term and intermediate outcomes.


This was a systematic review …

View Full Text


  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.